Updated March 31, 2026 · Last verified: March 31, 2026 · FDA status checked · Pricing verified · Trial data confirmed
Comparison Guide · March 31, 2026
Orforglipron vs Zepbound: Should You Wait for the Pill or Start Now?
Bottom line
Zepbound is FDA-approved, available right now, and produced an average of 20.9% body weight loss at the highest dose in clinical trials. Orforglipron is a once-daily pill with no needles and no fasting rules, with Lilly reporting potential U.S. action in Q2 2026 and planned self-pay pricing starting at $149/month if approved.
If you want the strongest weight loss results and you're okay with a weekly injection, Zepbound is the better choice today. If needles are a genuine dealbreaker, orforglipron is worth watching. And if you want a GLP-1 pill this week, oral Wegovy is already FDA-approved and available at pharmacies.
Both medications are made by Eli Lilly. They are not the same drug. Orforglipron is not “Zepbound in pill form.” It's a completely different molecule that targets one receptor instead of two — and that distinction changes everything about who should pick which, how much weight you'll lose, and what you'll pay.
We verified every clinical number directly from published trials, cross-checked pricing against manufacturer sources, and built the decision framework below so you can stop searching and start deciding.
Orforglipron vs Zepbound at a Glance
This is the comparison table most pages bury. We're putting it first.
| Orforglipron | Zepbound (tirzepatide) | |
|---|---|---|
| FDA Status | Not yet approved — Q2 2026 expected | FDA-approved (Nov 2023) |
| Available Today? | ❌ No | ✅ Yes |
| How You Take It | Daily oral pill | Weekly injection (auto-injector pen) |
| Mechanism | GLP-1 receptor agonist (single target) | Dual GLP-1 + GIP receptor agonist |
| Avg. Weight Loss (highest dose, 72 wks) | 12.4% of body weight (ATTAIN-1) | 20.9% of body weight (SURMOUNT-1) |
| At 250 lbs, that's roughly… | ~31 lbs lost | ~52 lbs lost |
| Food/Water Restrictions | None — taken without timing restrictions in trials | N/A (injection) |
| Self-Pay Cost | $149–$399/month (planned, if approved) | $299–$449/month (LillyDirect self-pay) |
| With Commercial Insurance | TBD after approval | As low as $25/month (savings card) |
| Also Approved / Studied For | Under review for obesity; T2D submission planned 2026 | Chronic weight management, T2D (Mounjaro), OSA |
| Can Maintain After Injectable? | Yes — ATTAIN-MAINTAIN trial supports this | N/A (this is the injectable) |
| Manufacturer | Eli Lilly | Eli Lilly |
Sources: ATTAIN-1 (NEJM, Sept 2025), ATTAIN-2 (Lancet, Nov 2025), ATTAIN-MAINTAIN (Eli Lilly, Dec 2025), ACHIEVE-3 (Lancet, Feb 2026), Zepbound U.S. prescribing information, Eli Lilly government agreement (Nov 2025). Pricing verified March 31, 2026.
Already know Zepbound is the right fit?
Check Current Zepbound Pricing and Eligibility →Should You Wait for Orforglipron or Start Zepbound Now?
This is the real question behind the search. Not “how are these drugs different” — you can see that in the table above. The actual question is: what should you do right now?
There are three smart paths. Not two. Three.
Path 1: Start Zepbound Now
This is the right move if:
- →You want the strongest weight loss results currently available — Zepbound's dual-receptor mechanism has produced the highest average weight loss of any FDA-approved GLP-1 medication
- →You're comfortable with a weekly injection (most patients report the auto-injector pen takes about 10 seconds)
- →Your insurance covers it — which could bring your cost down to $25/month with Lilly's savings card
- →You have type 2 diabetes alongside obesity — tirzepatide is approved for both (as Mounjaro for T2D, Zepbound for weight management) and its dual mechanism provides exceptional blood sugar control
- →You have obstructive sleep apnea — Zepbound is the only GLP-1 with an FDA-approved OSA indication
- →You don't want to wait. Every month without treatment is a month of potential progress you don't get back
And here's the part most pages won't tell you: starting Zepbound now doesn't lock you in forever. Clinical data from the ATTAIN-MAINTAIN trial shows you can potentially switch to orforglipron for maintenance later. We cover that data in detail below.
Path 2: Wait for Orforglipron
This makes sense if:
- →Needles are a genuine dealbreaker — not just “I'd prefer a pill” but “I will not start treatment if it requires injecting”
- →You can afford to wait. Lilly says potential U.S. action for obesity is expected in Q2 2026; trade outlets have reported a possible April 10 PDUFA target date
- →You want a daily routine with zero restrictions — in clinical trials, orforglipron was taken without food or water timing restrictions
- →You're most concerned about long-term cost and don't have commercial insurance — orforglipron's planned $149–$399/month pricing may be your most accessible entry point
- →You're in a relatively stable place health-wise and waiting won't put your health at meaningful risk
The risk is real: FDA decisions can be delayed, and even after approval, insurance coverage takes time. You'd likely need to use LillyDirect self-pay initially.
Path 3: Choose a GLP-1 Pill Available Right Now
Most comparison pages completely ignore this option. But it exists. The Wegovy pill (oral semaglutide) was FDA-approved in December 2025. This path makes sense if:
- →You want a pill, and you want it now — not pending an FDA vote, not sometime in Q2
- →You want a medication with cardiovascular outcome data — oral Wegovy is indicated to reduce the risk of heart attack, stroke, and cardiovascular death in certain patients
- →You've been saying “I'll start when the pill comes out” and keep pushing the date back — that pill is here, right now
The tradeoff: oral Wegovy requires strict morning fasting rules. Orforglipron had no such restrictions in clinical trials — a meaningful convenience advantage if it's approved. And injectable Zepbound still produces more weight loss on average than either pill.
Not sure which path fits? Take the free 60-second GLP-1 matching quiz →
Wait — Is Orforglipron the Pill Version of Zepbound?
No. And this is the single biggest misconception in this entire search space.
Orforglipron
A GLP-1 receptor agonist — activates one receptor to suppress appetite, slow digestion, and increase insulin secretion. It's a small-molecule drug (not a peptide), which is why it can be taken as a pill without special fasting rules. Traditional GLP-1 drugs like semaglutide are peptides that get broken down in your stomach — that's why they've historically required injection. Orforglipron sidesteps that problem entirely.
Zepbound (tirzepatide)
A dual GLP-1 and GIP receptor agonist — activates two receptors. That second receptor (GIP) appears to amplify the metabolic effects beyond what GLP-1 alone achieves. Researchers believe GIP plays a role in fat storage regulation and metabolic signaling that complements GLP-1's appetite suppression. This dual mechanism is the primary reason Zepbound consistently produces more weight loss in clinical trials.
Which Actually Works Better for Weight Loss?
⚠️ Important caveat: There is no head-to-head trial comparing orforglipron directly to Zepbound. The numbers below come from separate studies with different patient populations. Cross-trial comparisons are the best data available, but they're not the final word.
Orforglipron Weight Loss Data
ATTAIN-1 — adults with obesity, no diabetes (72 weeks)
NEJM, Sept 2025- 3,127 adults with obesity or overweight, no diabetes
- Highest dose (36mg): average weight loss of 12.4% of body weight (~27 lbs)
- 59% of patients on the highest dose lost at least 10% of body weight
- Up to 91% with prediabetes reached near-normal blood sugar levels
ATTAIN-2 — adults with obesity and type 2 diabetes (72 weeks)
Lancet, Nov 2025- Average weight loss of 10.5% of body weight (~23 lbs) at highest dose
ACHIEVE-3 — head-to-head vs oral semaglutide (52 weeks)
Lancet, Feb 2026- 1,698 adults with type 2 diabetes
- Orforglipron 36mg: 9.2% weight loss (19.7 lbs) and 2.2% A1C reduction
- Oral semaglutide 14mg: 5.3% weight loss (11.0 lbs) and 1.4% A1C reduction
- Orforglipron won on both weight loss and blood sugar control
Zepbound Weight Loss Data
SURMOUNT-1 — adults with obesity, no diabetes (72 weeks)
NEJM, 2022- 2,539 adults with obesity, no diabetes
- Highest dose (15mg): average weight loss of 20.9% of body weight
- One-third of participants lost more than 25% of body weight
SURMOUNT-2 — adults with obesity and type 2 diabetes (72 weeks)
NEJM, 2023- Average weight loss of 15.7% of body weight at highest dose
What That Gap Looks Like in Real Pounds
| Starting Weight | Orforglipron (~12%) | Zepbound (~21%) | Difference |
|---|---|---|---|
| 180 lbs | ~22 lbs lost | ~38 lbs lost | 16 lbs |
| 220 lbs | ~26 lbs lost | ~46 lbs lost | 20 lbs |
| 250 lbs | ~30 lbs lost | ~53 lbs lost | 23 lbs |
| 300 lbs | ~36 lbs lost | ~63 lbs lost | 27 lbs |
That's a meaningful difference. But here's what those numbers don't show: 12% weight loss from a daily pill is still clinically significant. Research consistently shows that even 5–10% body weight loss can improve blood pressure, blood sugar, cholesterol, joint pain, sleep quality, and overall mortality risk. The question isn't whether 12% is “good enough” in absolute terms — it is, by any historical standard. The question is whether the extra ~9% from Zepbound is worth a weekly injection to you. That's a personal calculation.
If maximum weight loss is your top priority:
Check Current Zepbound Pricing and Eligibility →Cost: What Will You Actually Pay in 2026?
Drug pricing is confusing by design. Here's what we can verify right now.
Orforglipron — Planned Pricing, If Approved
| Lowest dose (LillyDirect self-pay) | $149/month |
| Higher doses (LillyDirect self-pay) | Up to $399/month |
| Medicare (GLP-1 Bridge Model, July 2026+) | ≤$50/month, if approved |
| Commercial insurance | Unknown until after FDA approval |
Planned prices — depend on FDA approval and could change.
Zepbound — Current Pricing, Available Now
| List price (wholesale) | $1,086/month — most don't pay this |
| LillyDirect self-pay (2.5mg) | $299/month |
| LillyDirect self-pay (5mg) | $399/month |
| LillyDirect self-pay (7.5mg–15mg) | $449/month (must refill within 45 days) |
| With commercial insurance + savings card | As low as $25/month |
| Medicare (GLP-1 Bridge Model, July 2026+) | ≤$50/month, no deductible |
The Real Cost Comparison
| Your Situation | Orforglipron | Zepbound | Who Likely Wins |
|---|---|---|---|
| Commercial insurance covers it | TBD | As low as $25/mo | Zepbound — can't beat $25 |
| Commercial insurance, no coverage | TBD | ~$499/mo | Likely orforglipron |
| Cash pay, no insurance | $149–$399/mo | $299–$449/mo | Competitive — orforglipron edges at lower doses |
| Medicare (July 2026+) | ≤$50/mo (if approved) | ≤$50/mo (Bridge Model) | Tied — both capped at $50 |
⚠️ The Zepbound refill timing trap
The $449 self-pay price for higher-dose Zepbound requires refilling within 45 days of your previous delivery. Miss that window and the price jumps to $499 for 7.5mg and $699 for 10/12.5/15mg. If you travel frequently or have an irregular schedule, set a reminder.
Want to know what Zepbound would actually cost with your coverage?
Check Pricing and Eligibility — No Commitment Required →The Real Convenience Tradeoff: Daily Pill vs Weekly Shot
On paper, “pill vs injection” seems like an obvious win for the pill. In practice, it's more nuanced.
Where orforglipron clearly wins
- No needles. Period. For the estimated 20–30% of adults with significant needle anxiety, this is transformative.
- No fasting rules. Unlike oral Wegovy (empty stomach, tiny sip of water, wait 30 minutes), orforglipron was taken in trials without any food or water timing restrictions.
- Simpler travel logistics. No cold packs, no sharps disposal, no TSA questions. Pills are inherently easier to travel with.
Where Zepbound might actually be easier
- Once a week vs every single day. Some people find it easier to remember one shot per week than a daily pill. If you forget daily medications, weekly dosing has an adherence advantage.
- Smoother drug exposure. Weekly injections provide more consistent drug levels throughout the week, which may contribute to fewer GI side effects.
- No new daily routine required. Pick one day, inject, done for the week.
Side Effects: The Tradeoff Nobody Wants to Talk About
Both medications cause GI side effects. That's the reality of every GLP-1 medication — they work partly by slowing digestion.
Orforglipron showed higher GI side effect rates
About 59% of orforglipron participants in ATTAIN-1 reported GI symptoms, and roughly 10% discontinued treatment due to side effects. Zepbound's prescribing information reports adverse reactions leading to discontinuation in 4.8–6.7% of patients. Daily oral dosing likely creates more frequent drug peaks that trigger nausea.
What both share
Nausea, vomiting, diarrhea, constipation, decreased appetite — GLP-1 class effects. Typically worst during dose titration and improve over time. Both use gradual dose escalation to minimize symptoms.
Zepbound's boxed warning
Carries an FDA boxed warning for risk of thyroid C-cell tumors observed in animal studies. Should not be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Orforglipron's final label is pending approval.
The bottom line
Orforglipron does NOT win on tolerability. If minimizing nausea is your top priority, Zepbound likely delivers a smoother experience. But 90%+ of orforglipron patients did tolerate the medication, and side effects generally improved over time.
Want a provider who supports you through the titration process?
Explore Zepbound with Clinical Support and Titration Guidance →Can You Start Zepbound Now and Switch to Orforglipron Later?
This might be the most important section on this page — and the one almost nobody else covers well.
The short answer: clinical trial data supports this as a viable strategy.
What the ATTAIN-MAINTAIN Trial Showed
In December 2025, Eli Lilly released results from ATTAIN-MAINTAIN — a first-of-its-kind study specifically designed to test what happens when you switch from an injectable GLP-1 to the orforglipron pill. Over 300 patients who had taken Zepbound or Wegovy for 72 weeks were re-randomized to either orforglipron (up to 36mg daily) or placebo for another 52 weeks.
Switchers from Wegovy → orforglipron
Maintained previously achieved weight loss with an average difference of just 0.9 kg (~2 lbs) at 52 weeks. That's near-total preservation of their results.
Switchers from Zepbound → orforglipron
Maintained weight loss with an average difference of 5.0 kg (~11 lbs) at 52 weeks. More regain than the Wegovy group — possibly because Zepbound's dual mechanism creates weight loss that a single-receptor pill can't fully sustain — but still meaningful progress preserved.
Placebo groups
Regained significantly more weight, confirming that orforglipron is actively maintaining the loss.
The Two-Phase Strategy
Phase 1 — Aggressive Weight Loss
Zepbound
Use Zepbound's dual-mechanism injection to achieve maximum weight loss. This is the heavy-lifting phase where Zepbound's superior efficacy matters most.
Phase 2 — Convenient Maintenance
Orforglipron
Once you've reached your weight loss goal, transition to the orforglipron pill. No more injections. Just a daily pill that helps you keep the progress you worked hard to achieve.
The fact that Lilly specifically designed a clinical trial to test this exact scenario tells you they see this as a real clinical pathway, not just a theoretical one.
If that strategy sounds right for your goals:
Ro includes clinical support, insurance concierge, and unlimited provider messaging in their Zepbound program.
Get Started with Zepbound →What If You Want a Pill Right Now?
If your main takeaway is “I want a pill, not a shot, and I want it today” — you actually have an option most comparison pages don't mention.
In December 2025, the FDA approved the Wegovy pill (oral semaglutide) for weight loss. It is available at pharmacies right now. It's also the only oral GLP-1 with demonstrated cardiovascular benefit data.
| Oral Wegovy (available now) | Orforglipron (pending approval) | |
|---|---|---|
| Available today? | ✅ Yes | ❌ No |
| Fasting required? | Yes — empty stomach, 30 min wait | No restrictions in trials |
| FDA-approved for weight loss? | ✅ Yes | Not yet |
| Cost | $149–$299/mo (NovoCare) | $149–$399/mo (planned) |
| CV outcome data? | ✅ Yes | Not yet |
Want to explore the oral GLP-1 path today?
Compare Oral Wegovy Options and Pricing →When Will Orforglipron Actually Be Available?
What if it's delayed?
FDA decisions can be postponed. A Complete Response Letter (CRL) could request additional data. If there's a delay, Zepbound and oral Wegovy remain proven options. Your weight loss journey doesn't have to be held hostage by any single regulatory decision.
We update this page within hours of any FDA announcement.
If You're [X], Pick [Y]: The Quick Decision Guide
If: Your top priority is maximum weight loss
→ Choose Zepbound.
The clinical data is clear — 20.9% average weight loss at the highest dose in SURMOUNT-1. No other FDA-approved GLP-1 comes close.
If: Needles are your absolute dealbreaker
→ Wait for orforglipron — or start oral Wegovy now.
If you refuse to inject, don't force it. Both oral options are legitimate paths. Oral Wegovy is available today. Orforglipron is expected to follow if approved.
If: You have commercial insurance that covers Zepbound
→ Start Zepbound now.
At $25/month with the savings card, there's no financial reason to wait. You're getting the most effective option at a fraction of its real cost.
If: You're paying cash with no insurance
→ Compare carefully.
Zepbound self-pay starts at $299/month. Orforglipron's planned pricing starts at $149/month. At maintenance doses, the gap narrows to ~$50/month. Factor in the wait for FDA approval.
If: You have type 2 diabetes
→ Lean toward tirzepatide.
Approved for T2D as Mounjaro and for weight management as Zepbound. Its dual mechanism produces exceptional blood sugar control alongside weight loss.
If: You have obstructive sleep apnea
→ Zepbound is the only option with an FDA-approved OSA indication.
Orforglipron is being studied for OSA but has no approval. If OSA is part of your medical picture, Zepbound has the label and the data.
If: You travel frequently
→ Orforglipron wins on logistics.
Pills are inherently easier to travel with than injectables. No cold packs, no pen disposal, no TSA questions.
If: You're on Medicare
→ Good news is coming from both sides.
Under the GLP-1 Bridge Model, Zepbound is available at ≤$50/month with no deductible from July 1, 2026. If orforglipron is approved, the same cap applies. LillyDirect self-pay is available now for Zepbound.
If: You're thinking long-term maintenance
→ Consider the start-injectable, switch-to-pill strategy.
Use Zepbound's superior efficacy for the initial loss phase, then transition to orforglipron for convenient long-term maintenance. ATTAIN-MAINTAIN data supports this.
What Real Patients Actually Care About
The needle anxiety is real — and valid
Research estimates that 20–30% of adults have needle aversion significant enough to affect their medical decisions. This isn't squeamishness. It's a real psychological response that keeps millions of people from accessing treatment that could dramatically improve their health. If that's you, the emergence of effective oral GLP-1 options is one of the most important developments in this drug class.
The cost conversation never ends
“What will it actually cost me?” might be the single most common question in every GLP-1 community. That's why we broke down the real pricing scenarios above — not the sticker price, but what you'd actually pay.
The “am I making the right choice?” anxiety
Here's the reassurance you need: there is no catastrophically wrong choice here. Both Zepbound and orforglipron (when available) are legitimate, well-studied medications from the same manufacturer. Starting Zepbound now doesn't prevent you from switching later. Waiting isn't going to derail your health. What matters most is that you choose a path and start moving forward.
Real experiences on Zepbound
People who start Zepbound consistently report two things: the injection was easier than expected, and the appetite suppression was more powerful than expected. The first few weeks often involve some adjustment — nausea is common during dose titration — but most patients describe a turning point where the medication “clicks” and food noise quiets dramatically.
Related guides
How We Verified This Page
What we used:
- Clinical trial data from NEJM and The Lancet
- Eli Lilly official investor releases (ATTAIN-MAINTAIN, ACHIEVE-3)
- Eli Lilly's official orforglipron FAQ
- Zepbound U.S. prescribing information
- Official Zepbound savings page for current pricing
- Eli Lilly's March 9, 2026 CMMI BALANCE Model statement
- Official Wegovy website for oral Wegovy availability
- Ro.com for provider access and program details
What we did NOT do:
- We did not claim orforglipron is FDA-approved — it is not
- We did not make head-to-head efficacy claims where no head-to-head trial exists
- We did not fabricate testimonials or patient quotes
- We did not claim orforglipron is “Zepbound in pill form”
- We did not use “clinically proven” for investigational products
Affiliate disclosure: This page contains affiliate links to Ro. If you sign up through our links, we may earn a commission at no additional cost to you. This does not influence our recommendations — our editorial methodology, provider evaluation criteria, and data verification are independent of any commercial relationship.
FAQ: Orforglipron vs Zepbound
Is orforglipron the same as Zepbound?
No. They're both made by Eli Lilly, but they're different medications with different mechanisms. Orforglipron is a GLP-1-only oral pill. Zepbound (tirzepatide) is a dual GLP-1/GIP injectable. Different molecules, different targets, different weight loss results.
Is orforglipron as effective as Zepbound for weight loss?
Not based on current data. Zepbound produced 20.9% average body weight loss at the highest dose in SURMOUNT-1, compared to 12.4% for orforglipron in ATTAIN-1. The gap is likely due to Zepbound's dual-receptor mechanism. No direct head-to-head trial has compared the two drugs.
When will orforglipron be available?
Eli Lilly says potential U.S. action for obesity is expected in Q2 2026. Trade outlets have reported a possible April 10, 2026 PDUFA target date. Orforglipron was selected for the FDA Commissioner's National Priority Review Voucher pilot program.
How much will orforglipron cost?
Lilly's planned self-pay pricing through LillyDirect: $149/month for the lowest dose, up to $399/month for higher doses, if approved. Medicare patients may access it at no more than $50/month under the GLP-1 Bridge Model, if approved, from July 1, 2026.
Can you switch from Zepbound to orforglipron?
Clinical trial data from ATTAIN-MAINTAIN supports this. Patients who switched from Zepbound to orforglipron maintained their weight loss with an average difference of 5.0 kg (~11 lbs) at 52 weeks. However, orforglipron isn't FDA-approved yet, so this transition isn't available today.
Is orforglipron the pill version of Zepbound?
No. This is a common misconception. Orforglipron is a completely different drug — a GLP-1-only small-molecule compound. Zepbound (tirzepatide) is a dual GLP-1/GIP peptide injectable. It is not an oral form of tirzepatide. Different mechanism, different results, different category of medication.
Which has worse side effects — orforglipron or Zepbound?
Orforglipron showed higher GI side effect rates in clinical trials — about 59% of ATTAIN-1 participants reported GI symptoms, with roughly 10% discontinuing treatment. Zepbound's prescribing information reports 4.8–6.7% discontinuation due to adverse reactions. Daily oral dosing may create more frequent drug peaks that contribute to nausea.
Should I wait for orforglipron or start Zepbound now?
Depends on your priorities. If you want maximum weight loss and can handle injections, start Zepbound — you can potentially switch to the pill for maintenance later using the ATTAIN-MAINTAIN strategy. If needles are a genuine barrier, the FDA decision is expected in Q2 2026. If you want a pill today, oral Wegovy is already FDA-approved and available.
Is there a GLP-1 pill I can take right now?
Yes. Oral Wegovy (semaglutide) was FDA-approved in December 2025 and is available at pharmacies. It requires fasting rules (empty stomach, wait 30 minutes), unlike orforglipron's no-restriction protocol in trials. But it's real, approved, and available today.
What if I have insurance that covers Zepbound?
Start Zepbound. With the savings card, you may pay as little as $25/month — likely less than orforglipron will cost at launch, even at the lowest dose. There's no financial reason to wait if you have commercial coverage.
What if I'm paying cash with no insurance?
Compare carefully. Zepbound self-pay starts at $299/month through LillyDirect. Orforglipron's planned pricing starts at $149/month. At lower doses, orforglipron is more affordable. At maintenance doses, the gap narrows to about $50/month. Factor in that orforglipron requires FDA approval first.
What if I have obstructive sleep apnea?
Zepbound is the only GLP-1 medication with an FDA-approved indication for moderate-to-severe obstructive sleep apnea. If OSA is part of your medical picture, Zepbound has the label and the clinical data. Orforglipron is being studied for OSA but has no approval.
What about Medicare coverage for GLP-1 medications?
Under Lilly's participation in the GLP-1 Bridge Model, Medicare Part D beneficiaries can access Zepbound at no more than $50/month with no deductible from July 1, 2026 through December 31, 2026. If orforglipron is approved, the same $50/month cap is expected to apply.
What to Do Next
You've seen the data. You understand the tradeoffs. Here are the clearest next steps.
“I'm ready to start Zepbound now.”
Zepbound is FDA-approved, available today, and produced 20.9% average weight loss at the highest dose. If your insurance covers it, you could pay as little as $25/month. Cash pay starts at $299/month through LillyDirect. Ro offers online consultations with licensed providers — including clinical support, insurance concierge, unlimited provider messaging, and titration guidance.
Check Current Zepbound Pricing and Eligibility →“I want a GLP-1 pill I can start today.”
Oral Wegovy is FDA-approved and available now. It does require morning fasting rules, but it's a real, proven, needle-free option you can access this week — with demonstrated cardiovascular benefit data behind it.
Compare Oral Wegovy Options and Pricing →“I'm still not sure which path is right for me.”
Your budget, insurance situation, medical history, comfort with injections, and personal goals all play a role. Our matching quiz asks the right questions and gives you a personalized recommendation in about 60 seconds.
Take the Free 60-Second GLP-1 Matching Quiz →Free · No signup · 60 seconds
References
- Zepbound (tirzepatide) U.S. Prescribing Information. Eli Lilly and Company.
- ATTAIN-1: Eli Lilly. “Lilly's oral GLP-1, orforglipron, delivers weight loss of average 27.3 lbs.” Published in New England Journal of Medicine, September 2025.
- ATTAIN-2: Eli Lilly. ATTAIN-2 results published in The Lancet, November 2025.
- ATTAIN-MAINTAIN: Eli Lilly. “Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins.” December 18, 2025. investor.lilly.com
- ACHIEVE-3: Eli Lilly. “Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide.” Published in The Lancet, February 2026.
- Eli Lilly. “What to Know About Orforglipron Oral GLP-1.” Updated February 2026. lilly.com
- Eli Lilly statement on CMMI BALANCE Model / GLP-1 Bridge Model. March 9, 2026. investor.lilly.com
- Eli Lilly. “Lilly and U.S. government agree to expand access to obesity medicines.” November 6, 2025. investor.lilly.com
- Zepbound Savings Page. zepbound.lilly.com. Verified March 31, 2026.
- Wegovy.com. “What to Pay for Wegovy.” Verified March 31, 2026.
This page is updated regularly as FDA decisions, pricing, and clinical data evolve. Last verified: March 31, 2026. This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any new medication.